MedTrace Logo

Efficacy and Safety of Yishen Daluo Yin Granule for Relapsing-Remitting Multiple Sclerosis

NCT07029867 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2026-02-04

No results posted yet for this study

Summary

The aim of this study is to evaluate the efficacy and safety of YSDLY granule in patients with RRMS. This will be a multi-center, randomized, double-blind, placebo-controlled study.

Conditions

  • Relapse Remitting Multiple Sclerosis

Interventions

DRUG

Yishen Daluo Yin granuls

The patient takes YSDLY granules or placebo twice a day.

DRUG

Placebo

The patient takes placebo (YSDL mimetic granules) twice a day.

Sponsors & Collaborators

  • First Affiliated Hospital of Jinan University

    collaborator OTHER

  • The Second Hospital of Hebei Medical University

    collaborator OTHER

  • Chinese PLA General Hospital

    collaborator OTHER

  • Ying Gao

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-15
Primary Completion
2026-10-31
Completion
2026-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07029867 on ClinicalTrials.gov